Victoria coroner links actor's death to unapproved CJC-1295 and Ipamorelin
On 28 October 2026, Victorian Coroner David Ryan published findings on the March 2025 death of Australian actor, martial artist, and stunt coordinator Richard Norton. The coroner found that Norton's death was triggered by injection of unapproved peptide products CJC-1295 and Ipamorelin — prescribed by a doctor, compounded by a licensed Queensland pharmacy, and taken in amounts exceeding the prescribed dose. Coverage describes the case as believed to be Australia's first confirmed fatality linked to unapproved peptide use. The recommendation that follows is aimed at the product class, not only the individual care pathway: the TGA should review benefits and risks of peptides such as CJC-1295 and Ipamorelin and consider whether further restrictions, including tighter scheduling, are warranted. For a research reference audience, this is a material Australian regulatory signal layered on top of Victoria's recent anaphylaxis advisories and the TGA's year-long compliance focus on unapproved peptides.
What the coroner found
Richard Norton, 75, died at Melbourne’s Alfred Hospital on 30 March 2025 after an out-of-hospital cardiac arrest pathway that reporting and the coroner’s findings associate with anaphylaxis and complications following peptide injection. Two days earlier, on 28 March, he had injected CJC-1295 and Ipamorelin. The products had been prescribed on 19 March after clinical discussion of experimental status and risks, including anaphylaxis listed on a consent form. Blood tests and related work-up preceded prescribing. The coroner found Norton had been administering amounts in excess of the dose prescribed; a nurse had already counselled him to return to the prescribed dose after he disclosed doubling. The findings treat the injection as the trigger of the fatal cascade while also noting underlying conditions including asthma and hypertrophic cardiomyopathy reported in secondary coverage. The legal and regulatory weight of the decision is the causation finding plus the product-level recommendation, not a criminal prosecution of the prescriber or pharmacy.
Why CJC-1295 and Ipamorelin sat in a grey therapeutic box
Neither CJC-1295 nor Ipamorelin is included on the Australian Register of Therapeutic Goods (ARTG) as an approved medicine for the uses Norton sought. In Australian law, products not on the ARTG are unapproved therapeutic goods unless a specific exemption, special access pathway, or other authority applies. Unapproved status does not automatically make every clinical use impossible: Australian practitioners have used compounding and special-access mechanisms for individual patients. What unapproved status does mean is that the TGA has not evaluated the product for quality, safety, and efficacy the way it would for a registered medicine. The coroner’s language tracks that gap directly. He was not satisfied it is appropriate for such peptides to remain available for routine prescribing by medical practitioners given acknowledged uncertainties on benefit and incompletely characterised risk, including anaphylaxis.
The TGA recommendation and the Schedule 4 versus Schedule 10 question
Coroner Ryan recommended that the Therapeutic Goods Administration review the therapeutic benefits and safety risks of peptides such as CJC-1295 and Ipamorelin and consider whether further restrictions ought to be imposed. Reporting of the findings discusses the possibility of moving substances from Schedule 4 (prescription-only) toward Schedule 10 (substances of such danger that sale, supply, and use are prohibited except for limited authorised purposes such as approved clinical trials). A coronial recommendation is not a TGA decision. The agency must still run its own risk assessment, consult, and — if it chooses to tighten scheduling or access pathways — use the formal instruments available under the Therapeutic Goods Act and the Poisons Standard. Researchers should treat the Norton findings as a high-visibility prompt for possible future TGA action, not as a completed reclassification.
How this sits beside Victoria’s anaphylaxis advisory and TGA enforcement
Days before the coroner’s findings were widely reported, Victoria’s Chief Health Officer issued Health Advisory 261027 (27 October 2026) describing thirteen notified anaphylaxis cases associated with unapproved peptide products since July 2025, including a late-September 2026 cluster. That advisory is a public-health signal about acute hypersensitivity risk. The Norton findings convert one fatal pathway into a formal coronial record naming specific GH-axis peptides. Together they sit inside a broader Australian enforcement year: TGA compliance priority messaging, NSW seizures, the BioV8 Federal Court advertising action, and counterfeit retatrutide safety communications. None of those actions is a United States FDA rule.
What this does not change in the United States
Peptide Hub documents U.S. compounding status separately from foreign enforcement. CJC-1295 and Ipamorelin remain research peptides without FDA approval for the wellness and recovery claims often attached to them in grey-market marketing. U.S. 503A compounding eligibility still turns on USP monographs, components of approved drugs, or appearance on the 503A bulks list after nomination, evaluation, and rulemaking. The Norton coronial finding does not amend the FD&C Act, does not bind FDA, and does not authorise or prohibit U.S. pharmacy compounding by itself.
Clinical and documentation context the findings emphasise
Secondary reporting notes that Medical Board review of the prescribing pathway included an expert view that evidence of safety, effectiveness, and benefit for human use of CJC-1295/Ipamorelin was insufficient, while still placing the clinical care within a reasonably expected standard given consent, prior history, and the experimental framing disclosed to the patient. Documentation quality was criticised in places as sparse. For educational purposes, the durable points are: excess of prescribed dose was part of the factual findings; consent forms listing anaphylaxis did not prevent a fatal outcome; and licensed compounding of an unapproved peptide is not the same thing as TGA evaluation of that peptide as a medicine.
What researchers should watch next
First, any TGA formal response to the coroner’s recommendation. Second, whether other Australian states echo Victoria’s anaphylaxis surveillance. Third, whether professional regulators issue practice notes that change prescribing of unapproved peptides before scheduling changes. Fourth, parallel international enforcement themes. Until the TGA acts, the accurate description is a concluded coronial finding with a live recommendation — not a finished Australian ban on CJC-1295 or Ipamorelin.
Editorial Note: This article is published for research and educational purposes only. Peptide Hub does not sell peptides, receive commissions from peptide vendors, or endorse any specific supplier. All compounds discussed are research peptides not approved for human therapeutic use except where specifically noted. This is not medical advice.